-

10:25:58 AM

GENE Stock News

GENE - Genetic Technologies Ltd.

03/27/23 8:00 AM

Nasdaq : GENE

low float

GeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial Fibrillation

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the US launch of three (3) new diseases taking the total

RHEA-AI

neutral

03/13/23 8:00 AM

Nasdaq : GENE

low float

Back-to-back Studies Validate geneType Breast Cancer Risk Test

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the

RHEA-AI

neutral

02/09/23 8:00 AM

Nasdaq : GENE

low float

New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewed

RHEA-AI

positive

02/07/23 10:00 AM

Nasdaq : GENE

offeringlow float

Genetic Technologies Announces Closing of $5 Million Registered Direct Offering

Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced the closing of its

RHEA-AI

neutral

02/06/23 8:00 AM

Nasdaq : GENE

low float

Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update. The innovation and development of this test is

RHEA-AI

positive

02/03/23 8:35 AM

Nasdaq : GENE

offeringlow float

Genetic Technologies Announces $5 Million Registered Direct Offering

Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into

RHEA-AI

neutral

02/03/23 8:00 AM

Nasdaq : GENE

low float

GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk

RHEA-AI

neutral

02/01/23 8:00 AM

Nasdaq : GENE

low float

GTG to form Strategic Alliance with global testing leader QIAGEN

Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic alliance

RHEA-AI

very positive

01/30/23 8:00 AM

Nasdaq : GENE

low float

Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth

Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health, wellness and serious diseases releases its Quarterly business update for the quarter ended 31 December

RHEA-AI

positive

01/24/23 8:00 AM

Nasdaq : GENE

low float

Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce a poster presentation by Dr Erika Spaeth at the prestigious

RHEA-AI

positive

1 2 3 4 5 6 Next